The Role of Protein Phosphatase 2A in Alzheimer's disease pathogenesis

Alexander Hoffman

B. Biomedical Science (Hons), University of Newcastle, 2014

A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy in Medical Biochemistry

March 2019

This research was supported by an Australian Government Research Training Program (RTP) Scholarship.

STATEMENT OF ORIGINALITY

I hereby certify that the work embodied in the thesis is my own work, conducted under normal supervision. The thesis contains no material which has been accepted, or is being examined, for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no previously published or written by another person, except where due reference has been made in the text. I give consent to the final version of my thesis being made available worldwide when deposited in the University's Digital Repository, subject to the provision of the Copyright Act 1968 and any approved embargo.

ACKNOWLEDGEMENT OF AUTHORSHIP

I hereby certify that the work embodied in this thesis contains published papers of which I am a joint author. I have included as part of the thesis a written declaration endorsed in writing by my supervisor, attesting to my contribution to the joint publications.

ALEXANDER HOFFMAN

Acknowledgements

This work is possible through the contributions of the Australian Government Research Training Program (RTP) scholarship program. I would also like to thank the University of Newcastle, The School of Biomedical Sciences and Pharmacy, and the Priority Research Centre for Brain and Mental Health, who generously provided my student stipend for the duration of my candidature.

I would also like to express sincere gratitude towards my supervisors, Associate Professor Estelle Sontag and Doctor Jean-Marie Sontag. Without their tireless efforts and investments of time and energy, this body of work would not be possible. Specifically, I would like to acknowledge their knowledgeability in the field of neurochemistry, for which I have developed a profound respect for over the past several years. Thank you for pushing me to be able to work at the level that you believed I could perform at.

Thanks are also due to my co-supervisor, Professor Alan Brichta and also Doctor Rebecca Lim. Without the use of your expertise, advice and lab space, much of the work enclosed would not be possible. Thanks are also due to Dr. Lauren Poppi, Hannah Drury, Arnab Ghosh, Shafiq Syed and Dr. Manish Kumar Jhamb for your time, advice and the donation of mouse tissue for the same work.

I acknowledge the Traditional Owners of this land, the Pambalong clan of the Awabakal nation, where the majority of this work was undertaken. I recognise their continuing connection to land, waters and culture, and I pay my respects to their Elders past, present and future. Sovereignty was never ceded.

To my colleagues who shared an office space with me over the past few years; Pedro, Satvik, David, Goce and Diana - thank you for the sincere, unusual, and sometimes downright absurd conversations that only the shared experience of a Ph.D. candidature could precipitate. I would also like to thank my supportive friends and family members, who have always been there to release the pressure valve. I'd like to specifically acknowledge the strong women in my life who have kept me honest and who I have limitless respect for.

To my partner, Danni, thank you for supporting me and pushing me in such a kind and emotionally generous way – without you, I may have been able to complete this, but I would not be a shadow of the person afterwards.

To my father, Andrew: since starting this journey, life has thrown some challenges our way. I'm glad we're both here to see this. Thank you for everything.

Contents

Chapter 1: Background and Rationale		
	1.1 Alzheimer's disease, a major neurodegenerative disorder	3
	1.2 Proteins implicated in the pathogenesis of Alzheimer's disease	5
	1.3 A nuanced role for PP2A in Alzheimer's disease	16
	1.4 PP2Ac Methylation: Classical and new modes of regulation	22
	1.5 PP2A methylation and cAMP/PKA signalling	28
	1.6 Regulation of PP2Ac Tyrosine phosphorylation by Src	33
	1.7 Hypotheses and Aims	39
Chapter 2: Materials and Methods	2.0 Reagents & Antibodies	43
	2.1 Cell culture and transfection	45
	2.2 Cell treatment	45
	2.3 Preparation of cellular homogenates	46
	2.4 Immunoprecipitation	48
	2.5 Analysis of neurite outgrowth	48
	2.6 Preparation of acute cortical slices from mouse brain	49
	2.7 MTHFR-deficient mouse models and dietary interventions	50

	2.8 Gel electrophoresis and Western blotting	51
	2.9 Statistics	51
Chapter 3: Regulation of I	PP2Ac methylation by cAMP-PKA signalling	52
	3.0 Rationale and Significance	53
	3.1 Introduction	54
	3.2 Results	57
	3.3 Discussion	73
	3.5 Concluding remarks	80

Chapter 4: CREB regulation and one-carbon metabolism83

4.0 Rationale and Significance	84
4.1 Introduction	86
4.2 Results	88
4.3 Discussion	95
4.4 Concluding remarks	98

Chapter 5: MTHFR deficiency deregulates regional brain Amyloid-β	101
precursor protein	

5.0 Rationale and Significance	102
	10

5.1 Introduction	103
5.2 Results	104
5.3 Discussion	111
5.4 Concluding Remarks	117

Chapter 6: PP2Ac regulation by tyrosine phosphorylation 119

	6.0 Rationale and Significance	120
	6.1 Introduction	121
	6.2 Results	123
	6.3 Discussion	132
	6.4 Concluding Remarks	134
Chapter 7: Discussion		138
	7.1 Rationale for this study	139
	7.2 Novel Regulation of PP2A Methylation	140
	7.3 Disturbed One-Carbon Metabolism and the regulation of CREB & APP	147
	7.4 Novel Insights into PP2Ac Tyrosine phosphorylation	153
	7.5 Conclusions and Perspectives	156
References		157
Appendix		184

Figures

Chapter 1	1.1 Alzheimer's disease risk factors	4
	1.2 Regulation of the Amyloid Precursor Protein.	6
	1.3 APP Thr668 phosphorylation contributes to A β formation	8
	1.4 Tau structure, function and dysfunction	9
	1.5 PP2A-ABαC holoenzyme formation	18
	1.6 One-carbon metabolism controls LCMT-1 activity and PP2Ac methylation	22
	1.7 Neuronal cAMP-PKA signalling	29
	1.8: Src family kinase structure	34
	1.9 Regulation of PP2Ac in Alzheimer's disease	40
Chapter 2	2.1 Macrodissection of mouse cortex	49
	2.2 Mouse models of MTHFR- and folate-deficiencies	50
Chapter 3	3.1 Pharmacological activation of PKA promotes PP2Ac demethylation	58
	3.2 PKA activation induces PP2Ac demethylation in acute preparations of mouse cortex	59
	3.3 Subcellular distribution of demethylated and methylated PP2Ac	60

3.4 Forskolin enhances the nuclear distribution of demethylated **61** PP2Ac and PME-1.

3.5 Incubation of N2a cells with Forskolin induces a loss of **62** membrane-associated PP2A-ABαC

3.6 Stimulation of cAMP/PKA signalling by Forskolin leads to **63** Nuclear enrichment of PP2Ac and Bα subunits

3.7 Activation of cAMP/PKA signalling does not result in **65** phosphorylation of PME-1 in COS-7 cells

3.8 : PP2Ac^{WT}-induced CREB dephosphorylation is **66** methylation-dependent

3.9 PME-1 inhibition impairs CREB phosphorylation 68

3.10 Effects of modulating PP2A methylation on cAMP/PKA- **70** dependent Tau phosphorylatio

3.11 PP2Ac methylation mediates Forskolin-induced N2a **72** neurite outgrowth

- 3.12 PP2Ac regulation by PKA in neurons 81
- Chapter 4 4.1 The one carbon metabolic cycle 84

4.2 CREB phosphorylation depends on methyl-group **87** availability

4.3 Folate deficiency impairs CREB phosphorylation in N2a **88** cells

4.4 Plasma metabolite analysis in MTHFR- and folate-deficient **89** *mice*

4.5 CREB expression is increased in the Cortex of young **90** MTHFR deficient mice

4.6 CREB expression and phosphorylation is deregulated in the **91** midbrain of young mice with moderate MTHFR deficiency

4.7 MTHFR deficiency and CREB in the cerebellum 92

4.8 Low-folate diets in the aged midbrain lead to deregulated **93** *CREB.*

4.9 One-Carbon metabolism and the regulation of CREB **99**

Chapter 5 5.1 MTHFR deficiency leads to increased APP phosphorylation **104** in the cortex, hippocampus and midbrain of young mice

5.2 Effect of MTHFR status and dietary folate on APP **105** expression and phosphorylation in old mice.

5.3 MTHFR and folate deficiencies induce brain-region specific **107** alterations in APP expression

5.4 Effect of MTHFR and folate status on GSK-3 β activity in **109** young and old mice

5.5 One-Carbon metabolism and the regulation of APP by PP2A **117**

Chapter 6 6.1 Ectopic expression of Src^{CA} mutant In N2a and COS-7 cells **122**

6.2 PP2Ac Tyrosine phosphorylation is enhanced by SrcCA **123** overexpression and Pervanadate treatment

6.3 Widely utilised commercial pTyr307-PP2Ac antibodies do **124** not specifically recognise tyrosine phosphorylated PP2A

6.4 PP2A is not significantly phosphorylated at Tyr307 in **125** response to Src^{CA} or PV

6.5 Expression of PP2Ac Tyrosine phosphorylation- **126** incompetent mutants in COS-7 cells

6.6 HA-PP2Ac^{#3} mutant is resistant to Src^{CA}-dependent tyrosine **127** phosphorylation.

6.7 The HA3-PP2Ac^{#3} mutant is resistant to PV-dependent **128** tyrosine phosphorylation

6.8 PP2Ac^{#3} blocks Src-mediated Serine/Threonine Tau **129** phosphorylation

6.9: Src Family kinase inhibition blocks PP2Ac-dependent **130** neurite outgrowth

6.10 Schematic representation of Src-mediated regulation of **136** PP2A by phosphorylation

Chapter 7 7.1 Disturbed one-carbon metabolism induces changes in Tau, **151** APP and CREB via PP2Ac demethylation

7.2 Involvement of PP2A in Alzheimer's disease pathogenesis 155

Tables

Table 1.1	Tau kinases and their functional importance in neurons	11
Table 1.2	Common Tau phospho-epitopes	12
Table 1.3	In vivo models of disturbed one-carbon metabolism	26
Table 2.1	Plasmids	43
Table 2.2	Antibodies	44
Table 7.1	Effects of PP2Ac expression and Forskolin on CREB and Tau phosphorylation.	144
Table 7.2	Changes in APP regulation as a consequence of disturbed one- carbon metabolism	149

Abbreviations

3R/4R	Three Repeat / Four Repeat Tau	5HT	5-Hydroxy-Triptamine (Serotonin)
ACh	Acetylcholine	AD	Alzheimer's Disease
AICD	Amyloid Intracellular Domain	AKAP	A-Kinase Anchoring Protein
AMPA	α-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid	APP	Amyloid-β Precursor Protein
Αβ	Amyloid-β	BACE	B-Amyloid Cleaving Enzyme
BDNF	Brain-Derived Neurotrophic Factor	BH4	Tetrahydrobiopterin
СА	Cornu Ammonis	CAMP	Cyclic Adenosine Monophosphate
CBD	Corticobasal Degeneration	CBS	Cystathionine-β-Synthase
cdk5	Cyclin-dependent protein kinase 5	CREB	cAMP-responsive element binding protein
CTF	Carboxy-Terminal Fragment	D _x R	Dopamine (1-5) Receptor
ERK	Extracellular Regulated Protein Kinase	FTD	Fronto-temporal dementia
GAP	Guanine triphosphate- hydrolysing enzyme Activating protein	GSK-3β	Glycogen Synthase Kinase 3β
НА	Hemagglutinin	Нсу	Homocysteine
ННсу	Hyper-homocysteinemia	JNK	c-Jun N-terminal Kinase
LCMT-1	Leucine Carboxyl- methyltransferase 1	LTD	Long-term depression

LTP	Long-term potentiation	mAChR	Muscarinic Acetylcholine receptor
MAP2	Microtubule associated protein 2	mGluR	Metabotropic glutamate receptor
Mid1	Midline 1 protein	МТ	Microtubule
MTHFR	5,10- methylene tetrahydrofolate reductase	NFT	Neufibrillary Tangle
NGF	Neurotrophic Growth factor	NMDA	N-Methyl-D-aspartate
OA	Okadaic Acid	PDE	Phospho-diesterase
PHF	Paired Helical Filaments	Pin1	Peptidyl- prolyl cis-trans isomerase NIMA- interacting 1
РКА	cAMP-dependent protein kinase A	PME-1	Protein Phosphatase Methylesterase 1
PP2A	Protein Phosphatase 2A	SAH	S-Adenosyl-Homocysteine
SAM	S-Adenosyl- Methionine	SAPP	Secreted Amyloid-β Precursor Protein
SH(x)	Src Homology Domain	tHcy	Total Plasma Homocysteine
TIPRL	Target of rapamycin signalling pathway regulator	TrkA	Tropomyosin Receptor Kinase A

Thesis Abstract

Sporadic Alzheimer's disease (AD) is the most prevalent form of dementia in Australia and worldwide. Studies on the Familial form of AD have identified many of the molecular participants in the pathophysiology of AD; included in these is the Amyloid- β (A β) Precursor Protein (APP), which undergoes proteolytic processing to yield one of the pathological hallmarks of AD, A β . Another major hallmark of AD is hyper-phosphorylated, oligomerised Tau protein, which aggregates into Paired Helical Filaments (PHFs), which are then liable to form Neurofibrillary Tangles (NFTs). In this Thesis, we aimed to interrogate potential links between these two major contributors to AD in order to untangle the disease process.

In order to extricate this pathological cascade, we consulted some of the risk factors associated with AD. Among some others, AD risk is heightened by impaired folate metabolism and elevated plasma homocysteine levels; these two conditions may arise through inadequate dietary consumption of folate and associated micronutrients, or genetic impairments in the processing of folate and methyl groups referred to as "One-Carbon Metabolism". A major intracellular signalling mediator which is dependent on the proper cycling of one-carbon groups is the enzymatic family known as Protein Phosphatase 2A (PP2A). Methylated PP2A is widely recognised as the major Tau phosphatase, and deregulated PP2A enzymes have been found to co-exist in AD pathology with hyperphosphorylated Tau and degenerated brain regions most affected in AD. In vivo models of One-Carbon metabolism also show that Tau phosphorylation is also significantly elevated in the brain. In this study, we used the same model, mice with genetic deficiencies in the 5,10-methylenetetrahydrofolate reductase (MTHFR) enzyme, which were fed a normal folate or folate-deficient diet. We were able to show that the regulation of APP expression and post-translational modification is altered in major substructures on the brain, which helps affirm the link between a risk factor for AD (impaired folate metabolism), existing evidence for this risk in AD showing that PP2A and Tau are dysregulated in this model, and the perturbation of APP regulation.

Since it is evidently a major enzyme deregulated in AD, we endeavoured here to tease apart how PP2A can be precisely controlled by post-translational modification in neurons. The two major post-translational modifications of PP2A are leucine methylation and tyrosine phosphorylation of the catalytic subunit.

Currently, the only known source of the control of PP2A methylation arises from dietary supply of methyl groups, or One-Carbon metabolism, as briefly described above. Some groups have presented evidence suggesting that activation of cAMP signalling in non-neuronal cells affect the activity state of PP2A, while others show similar evidence for changes in PP2A methylation with the initiation of cAMP signalling. We thus deemed it necessary to delineate a more precise understanding of if, and how cAMP signalling affects PP2A methylation in neurons. To do this, we specifically investigated the activity and kinase targeting of cAMP-dependent protein kinase A (PKA) in cultured N2a cells. Indeed, we were able to show that activation of PKA with the cAMP-generating drug Forskolin led to time-sensitive demethylation of PP2A. We also observed that overexpression of the catalytic subunit of PP2A (PP2Ac) reduced the PKAtargeted phosphorylation sites of Tau and the transcription factor CREB, which is heavily involved in learning and memory consolidation. We thereby demonstrate a novel mode of PP2A regulation with direct consequences for both AD pathogenesis and regulation of learning and memory.

PKA-mediated changes in PP2A methylation appeared to have such important consequences, so we also used the MTHFR- and folate-deficient mouse models described above to

investigate a major neural target of PKA and PP2A, CREB. We observed an interesting array of effects of disturbed One-Carbon metabolism on CREB expression and phosphorylation, which is linked to its transcription factor activity state. In the cortex and midbrain regions of mice with genetic deficiency of the MTHFR enzyme, CREB expression was altered, and CREB activity was elevated in the midbrain of these mice. Hence, in this thesis, we demonstrate that disturbed One-Carbon metabolism, which is related to multiple AD risk factors, dysregulates both APP and CREB, both of which are implicated in the AD process. These are linked through previous results from our lab showing that PP2A methylation and Tau phosphorylation are concurrently affected by this model in the same way they are dysregulated in AD pathology.

In contrast to methylation of the catalytic subunit, tyrosine phosphorylation of PP2Ac was first reported to catalytically inactivate the enzyme. Unfortunately, these results have never been corroborated *in vivo* using independent methodologies. Since tyrosine phosphorylated PP2A has been reported to accumulate in close proximity to dystrophic neurites in AD, we deemed it important to substantiate the nature of PP2A tyrosine phosphorylation. If we could confirm that PP2A tyrosine phosphorylation and inactivation occurs in neurons, this may elucidate novel neurotoxic cascades in AD. In two distinct cell lines, we were able to show that the non-receptor tyrosine kinase, Src indeed phosphorylates PP2A, but at two previously unidentified tyrosine sites. We also demonstrate that phosphorylation of one of these sites can impair the Tau phosphatase activity of PP2A in N2a cells.

In the following body of work, we explore the importance of post-translational modifications of PP2A in the context of AD pathogenesis. Using cellular, *in vivo* and *ex vivo* techniques, we use this enzyme to navigate the role of dietary and genetic disturbances in the regulation of major proteins disturbed in AD, specifically Tau, APP and CREB. The novel findings we present provide the foundation for future study in the dysregulation of PP2A in memory disturbances and neurotoxicity in the molecular course of AD.